Thematische Bibliographien / Pulmonary Pathophysiology

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Pulmonary Pathophysiology“

Autor: Grafiati
Veröffentlicht am 4. Juni 2021
Zuletzt aktualisiert am 19. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Pulmonary Pathophysiology" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Pulmonary Pathophysiology"

1

Cherniack, Neil S. „Pulmonary Pathophysiology“. Annals of Internal Medicine 131, Nr. 5 (07.09.1999): 399. http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00022.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Gonzalez, Norberto C. „PULMONARY PATHOPHYSIOLOGY“. Shock 11, Nr. 2 (Februar 1999): 152. http://dx.doi.org/10.1097/00024382-199902000-00018.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Grippi, Michael A. „PULMONARY PATHOPHYSIOLOGY“. Shock 5, Nr. 4 (April 1996): 311. http://dx.doi.org/10.1097/00024382-199604000-00013.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Chamarthy, Murthy R., Asha Kandathil und Sanjeeva P. Kalva. „Pulmonary vascular pathophysiology“. Cardiovascular Diagnosis and Therapy 8, Nr. 3 (Juni 2018): 208–13. http://dx.doi.org/10.21037/cdt.2018.01.08.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Gao, Yuansheng, und J. Usha Raj. „Pathophysiology of Pulmonary Hypertension“. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 9, Nr. 6 (22.11.2017): i—104. http://dx.doi.org/10.4199/c00158ed1v01y201710isp078.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Angerio, Allan D., und Peter A. Kot. „Pathophysiology of pulmonary edema“. Critical Care Nursing Quarterly 17, Nr. 3 (November 1994): 21–26. http://dx.doi.org/10.1097/00002727-199411000-00004.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Higenbottam, Tim. „Pathophysiology of Pulmonary Hypertension“. Chest 105, Nr. 2 (Februar 1994): 7S—12S. http://dx.doi.org/10.1378/chest.105.2_supplement.7s.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Klayton, Ronald J. „PULMONARY PATHOPHYSIOLOGY — THE ESSENTIALS“. Military Medicine 158, Nr. 2 (01.02.1993): A9. http://dx.doi.org/10.1093/milmed/158.2.a9a.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Shibuya, Kazutoshi, Chikako Hasegawa, Shigeharu Hamatani, Tsutomu Hatori, Tadashi Nagayama, Hiroko Nonaka, Tsunehiro Ando und Megumi Wakayama. „Pathophysiology of pulmonary aspergillosis“. Journal of Infection and Chemotherapy 10, Nr. 3 (2004): 138–45. http://dx.doi.org/10.1007/s10156-004-0315-5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Matthay, Michael A. „Pathophysiology of Pulmonary Edema“. Clinics in Chest Medicine 6, Nr. 3 (September 1985): 301–14. http://dx.doi.org/10.1016/s0272-5231(21)00366-x.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Pulmonary Pathophysiology"

1

Walsh, Robert Leo. „Leukocyte elastase and anti-elastases in pulmonary emphysema“. Title page, contents and abstract only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phw2261.pdf.

Der volle Inhalt der Quelle
Annotation:
Includes bibliographical references (leaves 218-249) The preferred theory to explain the aetiology of emphysema points to an imbalance in the protease-antiprotease systems within the lung with human leukocyte elastase and [alpha]1-protease inhibiter being the main candidates. Examines some aspects of this theory.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Muzaffar, Saima. „Reactive oxygen species and the pathophysiology of adult respiratory distress syndrome“. Thesis, University of Bristol, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.271916.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Tauriainen, M. Peter. „Negative pressure pulmonary edema, a clinical review and study of its pathophysiology“. Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp04/mq23521.pdf.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Otsuka, Kojiro. „Sputum YKL-40 Levels and Pathophysiology of Asthma and Chronic Obstructive Pulmonary Disease“. Kyoto University, 2012. http://hdl.handle.net/2433/152498.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

McLennan, Geoffrey. „Oxygen toxicity and radiation injury to the pulmonary system“. Title page, index and forward only, 1997. http://web4.library.adelaide.edu.au/theses/09PH/09phm164.pdf.

Der volle Inhalt der Quelle
Annotation:
Bibliography: leaves 168-184. The work in this study encompasses oxygen free radical related inflammation in the peripheral lung and in lung cells. Animal and human studies have been used. Methods include cell culture with function studies, protein chemistry, animal and human physiology, and cell and lung structure through histopathology, and various forms of electron microscopy. The work resulting from this thesis has formed an important basis for understanding acute and chronic lung injury.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Mittal, Manish [Verfasser]. „Role of NADPH oxidases and KDR channels in the pathophysiology of hypoxia induced pulmonary hypertension / Manish Mittal“. Gießen : Universitätsbibliothek, 2009. http://d-nb.info/1060563207/34.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Mason, Nicholas. „Mechanisms of altitude-related cough“. Doctoral thesis, Universite Libre de Bruxelles, 2012. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209711.

Der volle Inhalt der Quelle
Annotation:
The original work presented in this thesis investigates some of the mechanisms that may be responsible for the aetiology of altitude-related cough. Particular attention is paid to its relationship to the long recognised, but poorly understood, changes in lung volumes that occur on ascent to altitude. The literature relevant to this thesis is reviewed in Chapter 1.

Widespread reports have long existed of a debilitating cough affecting visitors to high altitude that can incapacitate the sufferer and, on occasions, be severe enough to cause rib fractures (22, 34, 35). The prevalence of cough at altitude has been estimated to be between 22 and 42% at between 4200 and 4900 m in the Everest region of Nepal (10, 29). Traditionally the cough was attributed to the inspiration of the cold, dry air characteristic of the high altitude environment (37) but no attempts were made to confirm this aetiology. In the first formal study of cough at high altitude, nocturnal cough frequency was found to increase with increasing altitude during a trek to Everest Base Camp (5300 m) and massively so in 3 climbers on whom recordings were made up to 7000 m on Everest (8). After 9 days at 5300 m the citric acid cough threshold, a measure of the sensitivity of the cough reflex arc, was significantly reduced compared with both sea level and arrival at 5300 m.

During Operation Everest II, a simulated climb of Mount Everest in a hypobaric chamber, the majority of the subjects were troubled above 7000 m by pain and dryness in the throat and an irritating cough despite the chamber being maintained at a relative humidity of between 72 and 82% and a temperature of 23ºC (18). This argued against the widely held view that altitude-related cough was due to the inspiration of cold, dry air.

In the next major hypobaric chamber study, Operation Everest III, nocturnal cough frequency and citric acid cough threshold were measured on the 8 subjects in the study. The chamber temperature was maintained between 18 and 24ºC and relative humidity between 30 and 60% (24). This work is presented in Chapter 2 and, demonstrated an increase in nocturnal cough frequency with increasing altitude which immediately returned to control values on descent to sea level. Citric acid cough threshold was reduced at 8000 m compared to both sea level and 5000 m values. Changes in citric acid cough threshold at lower altitudes may not have been detected because of the constraints on subject numbers in the chamber. The study still however demonstrated an increase in clinical cough and a reduction in the citric acid cough threshold at extreme altitude, despite controlled environmental conditions, and thus refuted the long held belief that altitude-related cough is solely due to the inspiration of cold, dry air.

If altitude-related cough is not simply due to the inspiration of cold, dry air, other possible aetiologies are:

•\
Doctorat en Sciences médicales
info:eu-repo/semantics/nonPublished

APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Yoshioka, Eliane Muta. „Alterações pulmonares e sistêmicas em modelo de lesão pulmonar aguda de etiologia pulmonar e extra pulmonar após ventilação mecânica de curto prazo“. Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/5/5144/tde-03092010-144329/.

Der volle Inhalt der Quelle
Annotation:
A inflamação pulmonar pode variar de acordo com o sitio primário da injuria e poder ser afetado pelo estresse mecânico gerado pela ventilação mecânica. (VM) Objetivos: estudar as eventuais diferenças na reposta pulmonar e sistêmica na lesão pulmonar aguda pulmonar (LPA P ) e extra pulmonar (LPA Exp) após ventilação mecânica. Métodos: Camundongos BALB/c foram divididos em doze grupos. Os grupos controle pulmonar (CP) e extra pulmonar (C Exp) receberam solução salina (SAL) ou Lipopolissacarideo (LPS) via intratraqueal (IT) ou intraperitoneal (IP) respectivamente. Os grupos foram submetidos ou não a simples manobra de pressurização (SMP) até 45 cm H2O. Resultados: Os grupos LPAP e LPAExp não ventilados apresentaram o mesmo nível de inflamação; uma diferença estatisticamente significativa na densidade de células inflamatórias foi observada no grupo LPA P VM (3,84±1,28 cels/2) comparado ao grupo LPA Exp VM ((1,75±0,14 cels/2), p=0,013. O mesmo foi observado na LPA P SMP (2,92±0,44 cels/2) comparado ao LPA Exp SMP (1,46±0,23 cels/2), p<0,0001. LPAP mostrou estatisticamente significante aumento no El (56,19 ± 12,26 cm H2O) em comparação ao LPA Exp SMP (26,88 ± 36,38 cm H2O) após SMP (p = 0,029). Nenhuma diferença estatisticamente significante foi observada no estresse oxidativo no rim. Conclusão: Observamos um padrão diferente da resposta inflamatória e mecânica pulmonar comparando LPA pulmonar e extra-pulmonar submetido à ventilação mecânica de curto prazo. Embora a ventilação mecânica represente uma ferramenta essencial para estabilizar o paciente critico, é necessário individualizar a abordagem do tratamento ventilatório
Lung inflammation may vary according to the primary site of injury and may be affected by the mechanical stress generated by mechanical ventilation (MV). Objectives: to address possible differences in lung and systemic responses in pulmonary and extra pulmonary ALI after mechanical ventilation. Methods: BALB/c mice were divided in twelve groups of six animals. In pulmonary and extrapulmonary control or ALI groups received either saline or LPS (intratracheally instilled or intraperitoneally injected), respectively. Ventilated groups were either recruited or not with a single recruitment maneuver (SRM) reaching 45 cm H2O. Results: At baseline ALI P and ALI EXP non ventilated groups presented the same level of inflammation; a statistically significant difference in density of inflammatory cells was noted in ALI P MV (3,84±1,28 cells/2) compared to ALI EXP MV (1,75±0,14 cells/2), p=0,013. The same was observed in ALI P SRM (2,92±0,44 cells/2) compared to ALI EXP SRM (1,46±0,23 cells/2) ventilated groups (p<0,0001). ALI P showed a statistically significant increase in El (56,19 ± 12,26 cm H2O) in comparison to ALI EXP (26,88 ± 36,38 cm H2O) after SRM (p = 0,029). No statistical differences were observed in kidney oxidative stress. Conclusion: We observed a different pattern of response in lung inflammation and mechanics comparing pulmonary and extra pulmonary ALI, submitted to short term mechanical ventilation. Although mechanical ventilation represents a fundamental tool to stabilize critical patients, it is essential to individualize the approach of the ventilatory treatment
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Rondelet, Benoît. „Médiation humorale de l'hypertension artérielle pulmonaire dans un modèle de cardiopathie congénitale à shunt systémo-pulmonaire chez le porcelet en croissance“. Doctoral thesis, Universite Libre de Bruxelles, 2008. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210373.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Aissa, Jamal. „Pathophysiologie et pharmacologie cardio-pulmonaire et inflammatoire du PAF-ACETHER“. Paris 5, 1993. http://www.theses.fr/1993PA05CD07.

Der volle Inhalt der Quelle
Annotation:
Le paf-acéther (paf) est un médiateur pro inflammatoire dérivé du métabolisme des lipides constitutifs des membranes cellulaires. Nous avons étudié les effets physiothologiques du paf dans le domaine cardio-pulmonaire et lors d'une inflammation locale et articulaire. L'injection de ce médiateur dans la circulation pulmonaire chez la brebis induit une thrombocytopénie et une leucopénie immédiate puis une accumulation leucocytaire pulmonaire décelable à la 5ème minute. On observe une hypertension pulmonaire indépendante du thromboxane B2 (TxB2). Toutes les réponses induites par le paf sont inhibées par un antagoniste spécifique de ce médiateur, le WEB 2086. L'administration du complexe héparine-protamine chez le lapin s'accompagne d'une production transitoire de paf associée à une thrombocytopénie et à une leucopénie et d'une production retardée mais prolongée de TxB2. L'effet protecteur du BN 52021, autre antagoniste spécifique du paf, sur la trombocytopénie et le niveau plasmique du TxB2 indique d'une part que le paf exerce un rôle précoce au niveau cellulaire, d'autre part que la production de TxB2 est partiellement médiée par le paf. Notre travail a également montré l'implication du paf dans l'arthrite induite par la carragénie chez le lapin, notamment dans sa phase aiguë. Un antagoniste spécifique du paf, le BN 50730, exerce une action préventive et curative sur l'arthrite. Dans le modèle du granulome inflammatoire induit par la carragénine chez le rat, le paf est produit in situ au cours de la phase aiguë mais également au cours du passage à la phase chronique ce qui suggère son implication à cette étape de la réaction inflammatoire. L'action du paf doit se concevoir en fonction de ses nombreux effets cellulaires et de ses interrelations avec d'autres médiateurs de l'inflammation. Les effets bénéfiques des antagonistes des récepteurs au paf pourraient représenter une alternative thérapeutique et un intérêt clinique, notamment dans l'inflammation chronique.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Pulmonary Pathophysiology"

1

Pulmonary pathophysiology. Philadelphia: Lippincott, 1995.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Pulmonary pathophysiology: The essentials. 7. Aufl. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

B, West John, Hrsg. Pulmonary pathophysiology--the essentials. 4. Aufl. Baltimore: Williams & Wilkins, 1992.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

West, John B. (John Burnard), Hrsg. Pulmonary pathophysiology: The essentials. 8. Aufl. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Pulmonary pathophysiology: The essentials. 3. Aufl. Baltimore: Williams & Wilkins, 1987.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

B, West John, Hrsg. Pulmonary pathophysiology--the essentials. 5. Aufl. Baltimore, Md: Williams & Wilkins, 1998.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Pulmonary pathophysiology: A clinical approach. 3. Aufl. New York: McGraw-Hill Medical, 2010.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Workshop on "Chronic Pulmonary Hyperinflation" (1988 Montescano, Italy). Chronic pulmonary hyperinflation. London: Springer-Verlag, 1989.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Pulmonary circulation: Diseases and their treatment. 3. Aufl. London: Hodder Arnold, 2011.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Bittar, E. Edward. Pulmonary biology in health and disease. Herausgegeben von Springer-Verlag. New York: Springer, 2002.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Pulmonary Pathophysiology"

1

Kaul, Sunny. „Pathophysiology“. In Managing Chronic Obstructive Pulmonary Disease, 1–12. West Sussex, England: John Wiley & Sons Ltd, 2008. http://dx.doi.org/10.1002/9780470697603.ch1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Vanzeller, Mafalda, Marta Drummond und João Carlos Winck. „Chronic respiratory failure – pathophysiology“. In Pulmonary Rehabilitation, 399–408. Second edition. | Boca Raton : CRC Press, [2020] | Preceded by Pulmonary rehabilitation / Claudio F. Donner, Nicolino Ambrosino, Roger Goldstein. 2005.: CRC Press, 2020. http://dx.doi.org/10.1201/9781351015592-41.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Rabinovitch, Marlene. „Pulmonary Vascular Pathophysiology“. In Pediatric Cardiovascular Medicine, 71–80. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781444398786.ch5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Lajoie, Annie C., Vincent Mainguy, SéBastien Bonnet und Steeve Provencher. „Pulmonary vascular diseases“. In Applied Respiratory Pathophysiology, 119–47. Boca Raton : CRC Press, [2017]: CRC Press, 2017. http://dx.doi.org/10.1201/9781315177052-7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Milot, Julie, und Mathieu Morissette. „Chronic obstructive pulmonary disease“. In Applied Respiratory Pathophysiology, 97–118. Boca Raton : CRC Press, [2017]: CRC Press, 2017. http://dx.doi.org/10.1201/9781315177052-6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Schols, Annemie M. W. J., und Emiel F. M. Wouters. „Pulmonary rehabilitation“. In Recent Advances in the Pathophysiology of COPD, 167–87. Basel: Birkhäuser Basel, 2004. http://dx.doi.org/10.1007/978-3-0348-7939-2_11.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Schrump, David S. „Pulmonary Malignancies: Pathophysiology and Treatment“. In Principles and Practice of Geriatric Surgery, 406–32. New York, NY: Springer New York, 2001. http://dx.doi.org/10.1007/978-1-4757-3432-4_29.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Rizzo, Alicia N., Dustin R. Fraidenburg und Jason X. J. Yuan. „Pulmonary Vascular Physiology and Pathophysiology“. In PanVascular Medicine, 4057–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-37078-6_202.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Rizzo, Alicia N., Dustin R. Fraidenburg und Jason X. J. Yuan. „Pulmonary Vascular Physiology and Pathophysiology“. In PanVascular Medicine, 1–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-37393-0_202-1.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Mitani, Yoshihide. „Pathophysiology and Genetics: BMPR2“. In Diagnosis and Treatment of Pulmonary Hypertension, 115–24. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-287-840-3_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Pulmonary Pathophysiology"

1

Zhao, Y. C., S. E. Rees, S. Andreassen und S. Kjaergaard. „Simulation of Pulmonary Pathophysiology During Spontaneous Breathing“. In 2005 IEEE Engineering in Medicine and Biology 27th Annual Conference. IEEE, 2005. http://dx.doi.org/10.1109/iembs.2005.1615892.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Ghanem, M., A. Justet, M. Jaillet, M. Hachem, T. Boghanim, A. Vadel, A. Mailleux und B. Crestani. „Involvement of FGFR4 in Pulmonary Fibrosis Pathophysiology“. In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4220.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Lammers, Steven R., Phil H. Kao, Lian Tian, Kendall Hunter, H. Jerry Qi, Joseph Albietz, Stephen Hofmeister, Kurt Stenmark und Robin Shandas. „Quantification of Elastin Residual Stretch in Fresh Artery Tissue: Impact on Artery Material Properties and Pulmonary Hypertension Pathophysiology“. In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206793.

Der volle Inhalt der Quelle
Annotation:
Pulmonary arterial hypertension (PAH) is characterized as a chronic elevation in mean pulmonary artery pressure (MPAP) resulting from increased hydrodynamic resistance and decreased hydraulic capacitance of the pulmonary circulatory system. These hemodynamic changes cause the heart to operate outside optimum pump efficiency. The heart compensates for the efficiency loss through ventricular hypertrophy which, if left untreated, will continue until cardiac failure results.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Siler, S. Q., D. Longo, J. Woodhead, C. Battista, Z. Kenz, S. Tallapaka, G. Liu, G. Generaux, S. Ermakov und L. Shoda. „Using Quantitative Systems Pharmacology Modeling to Understand the Pathophysiology of Idiopathic Pulmonary Fibrosis“. In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4648.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Alamer, Amal, Rhys Jones, Chris Ward, Michael Drinnan, Alexander John Simpson, Michael Griffin, Joanne Patterson und Ian Forrest. „Oropharyngeal swallowing pathophysiology in patients with idiopathic pulmonary fibrosis: A consecutive descriptive case series“. In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3370.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Dumas, Sébastien J., Frédéric Perros, Catherine Rucker-Martin, Elodie Gouadon, Marc J. C. Humbert und Sylvia Cohen-Kaminsky. „Glutamate And NMDA Receptors: New Signaling Pathway Involved In The Pathophysiology Of Pulmonary Hypertension“. In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4747.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Alamer, A., R. Jones, C. Ward, M. Drinnan, AJ Simpson, M. Griffin, J. Patterson und I. Forrest. „S127 Oropharyngeal swallowing pathophysiology in patients with idiopathic pulmonary fibrosis: A consecutive descriptive case series“. In British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2021. http://dx.doi.org/10.1136/thorax-2020-btsabstracts.132.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

He, M., K. Qing, N. Tustison, L. A. Myc, J. MacLeod, R. Nunoo-Asare, J. Cassani et al. „Probing Early-Stage Pulmonary Pathophysiology in Young Healthy E-cigarettes Users Using Hyperpolarized 129Xe MRI“. In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1113.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Tan, Yan, und Wei Tan. „Reducing Upstream Compliance Induces Downstream High Pulsatility Flow-Dependent Inflammatory Response in Pulmonary Endothelial Cells via TLR2/NF-KB Pathway“. In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80900.

Der volle Inhalt der Quelle
Annotation:
Pulmonary arterial hypertension (PAH) is a group of chronic, progressive and fatal diseases, characterized by the dysfunction of the small arteries and microvasculature in the pulmonary circulation. Due to high blood pressure and high resistance in the pulmonary arteries, PAH causes detrimental damage on the lung and right heart ventricle. If left untreated, PAH quickly becomes life threatening. Although the exact pathophysiology remains unknown, there is increasing evidence suggesting that inflammation likely plays an important role in inducing and perpetuating the PAH progress. Although anti-inflammatory therapy has been shown effective in certain connective-tissue-disease-associated PAH, this approach has not been tested in other PAH conditions. The potential benefit of anti-inflammatory therapy to treat various PAH conditions could be of importance and require further study on the possible pathological mechanisms underlying the therapeutic effects.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Lee, Namheon, Michael D. Taylor, Kan N. Hor und Rupak K. Banerjee. „Non-Invasive Calculation of Energy Loss in Pulmonary Arteries Using 4D Phase Contrast MRI Measurement“. In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80525.

Der volle Inhalt der Quelle
Annotation:
The recent development of energy based endpoints, to quantify the pathophysiology of congenital heart disease such as tetralogy of Fallot (TOF), requires accurate measurement of cardiac blood flow and pressure data. Consequently, invasive cardiac catheterization is required for those measurements. In this research we used 4D phase contrast magnetic resonance imaging (PC MRI) data to determine the pressure drop non-invasively. This enables us to obtain pressure-flow variation, which, in turn, allowed us to calculate energy loss along the branch pulmonary arteries (PA). Based on our result, we believe that the hemodynamic status of the PA of a subject can be non-invasively evaluated by both pressure drop and energy loss values along the PA.
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Pulmonary Pathophysiology"

1

Hurt, Holcombe H., Suzanne A. Hernandez, Wallace B. Baze, Theresa M. Tezak-Reid und Jill R. Keeler. Pathophysiologic Mechanisms of Three Pulmonary Edemagenic Compounds: The Role of Toxic Oxygen Species. Fort Belvoir, VA: Defense Technical Information Center, April 1992. http://dx.doi.org/10.21236/ada251135.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Pulmonary Pathophysiology" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie